These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is anemia of cancer different from chemotherapy-induced anemia? Steensma DP J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523 [No Abstract] [Full Text] [Related]
4. Epoetin alfa and darbepoetin alfa go head to head. Steensma DP; Loprinzi CL J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021 [No Abstract] [Full Text] [Related]
5. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. Steensma DP J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668 [No Abstract] [Full Text] [Related]
6. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa. Longfield V; Gebhart B; Hayward L J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548 [No Abstract] [Full Text] [Related]
7. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia. Koopman W; Iakiri S J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554 [No Abstract] [Full Text] [Related]
9. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia. Yang MC Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351 [No Abstract] [Full Text] [Related]
10. Erythropoietin, the FDA, and oncology. Steinbrook R N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025 [No Abstract] [Full Text] [Related]
11. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. Bohlius J; Engert A; Schwarzer G JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112 [No Abstract] [Full Text] [Related]
12. Darbepoetin alfa and history of thromboembolic events. Ferretti G; Felici A; Cognetti F J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373 [No Abstract] [Full Text] [Related]
13. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
15. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia". Coiffier B Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359 [No Abstract] [Full Text] [Related]